The decision comes at a crucial juncture in the US's vaccination effort, which has gained speed in recent weeks at the same time a worsening outbreak grips the upper Midwest.
President Joe Biden described the approval as an encouraging development in efforts to end the Covid-19 crisis and said this is exciting news for all US citizens.
If J&J's phase 3 trial report very strong efficacy, it will be the single-shot vaccine that can be stored and transported at refrigerator temperatures unlike Pfizer and Moderna.
More than 90% of participants made immune proteins within 29 days after receiving the shot & all participants formed the antibodies within 57 days, according to the report.
The deal comes after a study showed Johnson & Johnson’s candidate vaccine generated strong antibody response in primates and provided protection with a single dose.
J&J announced in June that it had accelerated vaccine trials with ambitions of launching human studies in mid-July. The company will dose its first patients on 22 July in Belgium.
The chipmaker at the heart of the AI revolution may be the most influential stock in Wall Street history. Nvidia has been the primary driver of the market’s gains since the start of 2023.
ISRO’s LMV3 rocket set off the CMS-03 satellite from Sriharikota Sunday. It weighs 4,410 kg, will primarily serve Indian Navy and has a life of at least 15 years.
This world is being restructured and redrawn by one man, and what’s his power? It’s not his formidable military. It’s trade. With China, it turned on him.
COMMENTS